Navigation Links
Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
Date:2/4/2013

Norwood, MA (PRWEB) February 04, 2013

Infinata’s BioPharm Insight™ capped another year of global expansion in 2012. BioPharm Insight offers subscribers the unique combination of comprehensive market analytics, a database of key industry contacts and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists.

Ruth McHenry, Managing Director of Infinata, said, “BioPharm Insight continues its aggressive growth to meet the needs of industry professionals. Every day we work closely with our customers to understand and solve the challenges they face. I am so proud to say that in 2012 we met and exceeded all targeted areas of growth.”

New Features & Functionalities

New User Interface – BioPharm Insight’s completely redesigned user interface (UI) features a customizable homepage, easier navigation, and interactive charts and graphs. These enhancements allow subscribers to filter data and intelligence to fit their needs, allowing them to identify business opportunities as soon as they arise.

Increased Scope of Data – In addition to a new UI, BioPharm Insight continued to improve the scope of data provided to subscribers with the addition of:

  •     SEC filings
  •     NIH grant data
  •     Medicaid data
  •     EudraCT studies (BioPharm Clinical™)
  •     Expected Catalysts Calendar – by compiling study start and end dates, patent expirations and commercial launches by forecasts, BioPharm Insight provides the most comprehensive calendar of upcoming catalysts.

Analytics – Last year BioPharm Insight added the following analytics to further improve subscribers’ ability to find and use data quickly and efficiently:

  •     CRO activity
    '/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
4. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
5. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
6. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
7. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
8. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Plant disease specialists from around the ... Annual Meeting of The American Phytopathological Society. Details ... now at APSnet.org/meet . , The Preliminary Daily ... be held August 1-5, 2015 in Pasadena, California, U.S.A. ... Workshops, and committee meetings, all carefully balanced to deliver ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery made ... The improvement in histological quality provided the detail ... all daughter cells. , After processing with Ultralight ... at 1000-1600x using light microscopy. Phylogenetic and ... daughter cells displayed predominant binary features --- one ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... G. Rice , Ph.D., Chairman, President and Chief Executive ... Conference on Tuesday, March 10 th at 9:30 ... Laguna Niguel, CA. Dr. Rice will provide ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... Elbit Medical,Imaging Ltd. (Nasdaq: EMITF ) ("EMI") today ... has entered into definitive agreements,with one of the leading ... of a large scale mixed-use project located in,Bangalore, Karnataka, ... an Indian company to be,held in equal parts by ...
... PRINCETON, N.J., Oct. 22 Pharmacopeia,(Nasdaq: PCOP ), ... molecule therapeutics, today announced that Dr. Leslie J. Browne,President ... the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare,Conference. ... 2007, at the New,York Palace Hotel in New York ...
... Boston,Scientific Corporation (NYSE: BSX ) today ... from its TAXUS ARRIVE 1 and 2 registries, ... Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The pooled ... and repeat,revascularization through two years in complex patients ...
Cached Biology Technology:Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 2Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 3Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India 4Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 4ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... long looked to the future when a damaged heart could ... A study published in the February issue of Circulation ... that heart stem cells from children with congenital heart disease ... Sunjay Kaushal, MD, PhD, surgeon ...
... the field of cardiac therapeutics have long looked to the ... by using one,s own heart cells. A study published in ... of the American Heart Association, shows that heart stem cells ... the damaged heart in an animal model. ...
... scientist is digging deep to solidify information about potential ... Tungsten is a naturally occurring metallic element that in ... incandescent lightbulb filaments and X-ray tubes. In an ... replacing lead in fishing weights and in ammunition for ...
Cached Biology News:Stem cells show promise in repairing a child's heart 2Using a child's own stem cells to repair their heart looks promising 2National study explores the reaction and transport of tungsten in drinking water 2
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
Biology Products: